Piper Jaffray analyst Erinn Murphy weighed in this week with some thoughts on Genesco's recent disappointing earnings report and the outlook for the retailer's shares. She says investors will need to be patient for a while and that this year's holiday shopping season will provide an important read on how Genesco CEO Bob Dennis and his team have done cleaning up the inventory at their Lids division. Without a near-term catalyst, Murphy has trimmed his EPS forecast and lowered her price target for Genesco to $67 from $69. The stock (Ticker: GCO) is changing hands this morning at $67.16.
Avondale Partners analyst Paula Torch has raised her price target for Nashville-based AmSurg to $74 from $69.
The firm has maintained its 'market outperform' for the company, saying its raised guidance for revenues in a range of $2.46 billion to $2.48 billion could be conservative.
"[AmSurg] is executing on its JV partnerships, cross-selling initiatives, and we believe the pipeline for acquisitions remains plentiful," Torch said in a report issued Wednesday.
Shares of AmSurg (Ticker: AMSG) were up to $64.75 Thursday morning. Year to date, they've climbed 18 percent.
JP Morgan analyst Matthew Boss has relaunched coverage of Dollar General. Boss gave the Goodlettsville company an 'overweight' rating and a price target of $85. Shares of Dollar General (Ticker: DG) were up to $71.57 Tuesday morning. In the last 6 months, they're up 12 percent.
Avondale Partners analyst Paula Torch reiterated her 'market outperform' rating for LifePoint Hospitals, as well as her price target of $84.
In a report issued Friday, Torch said LifePoint's free cash flow and relationship with Duke University Health System would allow the Nashville company to take advantage of the strong health care M&A environment.
Further, Torch said health reform has continued to benefit LifePoint, particularly in volumes and payer mix. The company's self-pay admissions were down 42 percent on a same store basis in Q4, down to less than 5 percent of total admissions in the quarter.
However, a reversal of reform would "likely have a negative impact on the stock," Torch said, despite no material change in operations. The report did not express concern over the Supreme Court decision tackling insurance subsidies in states using the federal health care marketplace.
Torch also said that LifePoint's quality initiatives would "help it stand out in an environment where value is becoming more prolific, and we believe the company well set for another strong year." The firm adjusted its guidance for 2015, estimating $5.1 billion in revenue, $704 million in adjusted EBIDTA and $4.01 in earnings per share.
Shares of LifePoint (Ticker: LPNT) closed last week at $69.04. In the last three months, they're up 7 percent.
Robert W. Baird analyst Whit Mayo upgraded his AmSurg rating Friday to 'outperform' from 'neutral.' Mayo also boosted his price target for the company to $55 from $44.
Shares of the ambulatory surgery company (Ticker: AMSG) were down nearly 10 percent last week, following news that the company is offering almost 10 million shares to finance its acquisition of Sheridan Healthcare. Year to date, shares are down slightly. However, they're up 28 percent in the last 12 months.
Goldman Sachs analyst Stephen Grambling cut his rating on Dollar General Corp. Tuesday to 'buy' from 'conviction buy.' Grambling's price target on the company was unchanged at $72. Shares of Dollar General (Ticker: DG) were up slightly to $61.73 Tuesday afternoon. Year to date, they're up 2.3 percent.
Moody's Investment Service analyst Christopher Wimmer upgraded his rating on the health care REIT Thursday to 'positive' from 'stable.' "Healthcare Realty Trust's focus on medical office buildings and outpatient services provides very good earning stability," he said in a report. Wimmer did not set a price target for the company, which he noted had a "limited opportunity to grow relative to more diversified health care REIT's, given the [medical office building]-focused nature of its platform." Shares of the company (Ticker: HR) were up to $25.56 Friday. Year to date, they're up nearly 20 percent.
Analyst Fred Lowrance at Avondale Partners says the Gaylord Opryland Resort & Convention Center could perform better than expected this year in part because recovering from last year's flooding may have set a new baseline. He says the floods "left management and investors with limited ability to project what the newly renovated [...] property may be able to produce with a full year of uninterrupted operations." (For the record, Gaylord told investors last month it is looking for consolidated cash flow from Opryland of between $73 million and $77 million.)
Lowrance also is constructive on shares of Gaylord, which he rates 'market outperform,' because the company is not as reliant on actual room rates as it is on getting more visitors to its facilities, where they spend a ton on food and drink. He sees Gaylord stock (Ticker: GET) rising from the mid-$30s to $51.
POSTDATA: WARRANTY DEEDS